Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
2017 Standout
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
2013 StandoutScienceNobel
Ethoxyfagaronine, a synthetic analogue of fagaronine that inhibits vascular endothelial growth factor-1, as a new anti-angiogeneic agent
2014 StandoutNobel
Signaling pathway of MAPK/ERK in cell proliferation, differentiation, migration, senescence and apoptosis
2015 Standout
Cellular Cholesterol Depletion Triggers Shedding of the Human Interleukin-6 Receptor by ADAM10 and ADAM17 (TACE)
2003
The pro- and anti-inflammatory properties of the cytokine interleukin-6
2011 Standout
A cytokine-mediated link between innate immunity, inflammation, and cancer
2007 Standout
Caveolin-1-deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue
2003
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways
2005 StandoutNobel
New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin
2008 Standout
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
2019 Standout
ACG Clinical Guidelines: Diagnosis and Management of Celiac Disease
2013 Standout
IL-6 as a keystone cytokine in health and disease
2015 Standout
Inflammation and Colon Cancer
2010 Standout
Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
2013
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines
2012
An Akt/β-Arrestin 2/PP2A Signaling Complex Mediates Dopaminergic Neurotransmission and Behavior
2005 StandoutNobel
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Cholesterol and prostate cancer
2003
STATs in cancer inflammation and immunity: a leading role for STAT3
2009 Standout
Survival and Proliferation Factors of Normal and Malignant Plasma Cells
2003
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
2016
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial
2012
Enteropathy-associated T-cell lymphoma: A review on clinical presentation, diagnosis, therapeutic strategies and perspectives
2010
The STATs of cancer — new molecular targets come of age
2004 Standout
Anti‐cancer properties of anthraquinones from rhubarb
2006 Standout
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
2014 Standout
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
A Decade of Progress in Lymphoma: Advances and Continuing Challenges
2010
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Novel disease targets and management approaches for diffuse large B-cell lymphoma
2010
Diffuse large B-cell lymphoma
2013
Muscle as an Endocrine Organ: Focus on Muscle-Derived Interleukin-6
2008 Standout
The role of IL-6 and STAT3 in inflammation and cancer
2005 Standout
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
2017 Standout
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
2012
The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical–dependent and Jun NH2-terminal kinase–dependent mechanism
2004
FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance
2005
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
2003 Standout
2016 US lymphoid malignancy statistics by World Health Organization subtypes
2016 Standout
Follicular Helper CD4 T Cells (TFH)
2011 Standout
Caveolin-1 Maintains Activated Akt in Prostate CancerCells through Scaffolding Domain Binding Site Interactions with andInhibition of Serine/Threonine Protein Phosphatases PP1 andPP2A
2003
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Isatuximab Plus Pomalidomide/Dexamethasone Versus Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma: Icaria Phase Iii Study Design
2017
Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor α
2003
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2011
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
2016
The JAK/STAT signaling pathway
2004 Standout
Metabolic Dysregulation and Adipose Tissue Fibrosis: Role of Collagen VI
2008 Standout
Advances in biology of multiple myeloma: clinical applications
2004
Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies
2010
Lenalidomide efficacy in activated B ‐cell‐like subtype diffuse large B ‐cell lymphoma is dependent upon IRF 4 and cereblon expression
2012
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
2004
Works of Craig E. Cole being referenced
Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
2008
Essential Role of Caveolae in Interleukin-6- and Insulin-like Growth Factor I-triggered Akt-1-mediated Survival of Multiple Myeloma Cells
2003
Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
2016
Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
2009